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ABSTRACT
Background: The role of nutrition in the primary prevention
of peripheral artery disease (PAD), the third leading cause of
atherosclerotic cardiovascular disease, is undetermined. Flavonoids
may attenuate atherosclerosis and therefore persons who consume
flavonoid-rich foods may have a lower risk of developing PAD.
Objectives: We aimed to examine the association between flavonoid
intake and PAD hospitalizations and investigate if the association
differs according to established risk factors for PAD.
Methods: Baseline data from 55,647 participants of the Danish
Diet, Cancer, and Health Study without PAD, recruited from 1993
to 1997, were cross-linked with Danish nationwide registries.
Flavonoid intake was calculated from FFQs using the Phenol-
Explorer database. Associations were examined using multivariable-
adjusted restricted cubic splines based on Cox proportional hazards
models.
Results: After a median [IQR] follow-up time of 21 [20–22] y, 2131
participants had been hospitalized for any PAD. The association
between total flavonoid intake and total PAD hospitalizations was
nonlinear, reaching a plateau at ∼750–1000 mg/d. Compared with
the median flavonoid intake in quintile 1 (174 mg/d), an intake
of 1000 mg/d was associated with a 32% lower risk of any PAD
hospitalization (HR: 0.68; 95% CI: 0.60, 0.77), a 26% lower risk of
atherosclerosis (HR: 0.74; 95% CI: 0.62, 0.88), a 28% lower risk
of an aneurysm (HR: 0.72; 95% CI: 0.59, 0.88), and a 47% lower
risk of a hospitalization for other peripheral vascular disease (HR:
0.53; 95% CI: 0.42, 0.67). A higher total flavonoid intake was also
significantly associated with a lower incidence of revascularization
or endovascular surgery and lower extremity amputation. The
association between total flavonoid intake and PAD hospitalizations
differed according to baseline smoking status, alcohol intake, BMI,
and diabetes status.
Conclusions: Ensuring the adequate consumption of flavonoid-rich
foods, particularly in subpopulations prone to the development of
atherosclerosis, may be a key strategy to lower the risk of PAD.
Am J Clin Nutr 2021;113:187–199.
Keywords: nutrition, peripheral artery disease, primary prevention,
cohort study, lifestyle
Introduction
Peripheral artery disease (PAD) is the atherosclerotic obstruc-
tion, or ischemia, of arteries and most commonly manifests in
the lower extremities (1). PAD prevalence rises steeply with age;
in high-income countries, such as Denmark, PAD prevalence
is <7% for persons in their fifties, >10% for persons in their
sixties, and >18% for persons in their eighties (2). In 2010, >200
million adults worldwide had PAD (2). With the aging of the
global population, it is likely that PAD will become increasingly
common (2). PAD is associated with cardiovascular disease
morbidity and mortality (3) and the most common symptom of
PAD, intermittent claudication, can induce considerable suffering
and limit walking ability (4). Furthermore, severe PAD can
lead to limb ischemia and amputations of the lower extremities.
The public health significance of PAD calls for evidence-based
primary prevention strategies.
The role that nutrition plays in the primary prevention of
PAD is currently uncharacterized. Flavonoids, polyphenolic com-
pounds found ubiquitously in plant-derived foods and beverages
such as fruits, vegetables, dark chocolate, tea, and red wine (5),
have been shown to improve NO bioavailability and endothelial
function and decrease blood pressure and inflammation (6).
Am J Clin Nutr 2021;113:187–199. Printed in USA. © The Author(s) 2020. Published by Oxford University Press on behalf of the American Society for
Nutrition. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommon
s.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
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The main risk factors for PAD are age, smoking, and diabetes
mellitus. They are thought to contribute to PAD development
by an increase in inflammation, increase in arterial stiffness,
decrease in NO, increase in oxidative stress, and decrease in
vasodilation (7). Thus, flavonoid-rich foods could be important
moderators of PAD. Although there is some evidence that higher
flavonoid intakes are associated with a lower incidence of PAD
(8), larger, longer-term epidemiological studies are needed to
further examine potential associations.
We have previously shown that higher total flavonoid
intakes are associated with lower atherosclerotic cardiovas-
cular disease hospitalizations, and, more specifically, lower
PAD hospitalizations (9). However, unexplored areas include
whether the prevalence of risk factors modifies the association
between flavonoids and incidence of PAD hospitalization;
associations of individual flavonoid subclasses and individual
flavonoid compounds with PAD; associations of flavonoids
with subtypes of PAD such as atherosclerosis, aneurysm,
embolism or thrombosis, and other peripheral vascular diseases
(PVDs); and associations of flavonoids with PAD-related pro-
cedures such as revascularizations or endovascular surgery, and
amputations.
Therefore, the primary aim of this study was to investigate
the association of total flavonoid and flavonoid subclass intakes
with PAD hospitalizations in the Danish Diet, Cancer, and Health
cohort. Secondary aims were to investigate whether these associ-
ations differed according to the presence of risk factors for PAD.
Methods
Study population
Participants were recruited from the greater areas of Copen-
hagen and Aarhus between 1993 and 1997 as part of the Danish
Diet, Cancer, and Health study. Of the 57,053 participants
recruited, 56,468 completed an FFQ and were without a cancer
diagnosis before enrollment. All Danish residents are assigned
a unique and permanent number allowing cross-linking of
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participants to nationwide registers. The following databases
were cross-linked to the cohort: the Civil Registration System,
the Integrated Database for Labor Market Research, and the
Danish National Patient Register, which contains information
on all hospital admissions in Denmark since 1978. For all
admissions this includes 1 primary diagnosis and ≥1 secondary
diagnoses defined by the International Classification of Diseases
(ICD): the 8th revision (ICD-8) until 1993 and the 10th revision
(ICD-10) from 1994 (10). Participants were excluded if they
had improbable energy intakes [<2092 kJ/d (<500 kcal/d)
and >20,920 kJ/d (>5000 kcal/d)] (n = 202), or if they had
missing covariates or were extreme outliers (n = 218). Finally,
participants were excluded if they had any prevalent PAD
(n = 401): a prior diagnosis of atherosclerosis (ICD-8: 440, 414;
ICD-10: I70), aortic aneurysm (ICD-8: 441; ICD-10: I71), other
aneurysm (ICD-8: 442; ICD-10: I72), other PVD (ICD-8: 443;
ICD-10: I73), or arterial embolism and thrombosis (ICD-8: 444;
ICD-10: I74) (Supplemental Figure 1).
This study was approved by the Danish Data Protection
Agency (Ref no. 2012-58-0004; I-Suite nr: 6357; VD-2018-117).
Exposures
Exposures were intakes of total flavonoids, flavonoid sub-
classes, and individual flavonoid compounds with mean in-
takes > 5 mg/d. The calculations of flavonoid intake we used have
been described previously (11). Briefly, estimates of the flavonoid
content of all foods and beverages in the FFQ were obtained
from the Phenol-Explorer database (12). Because the average
intakes of isoflavones, dihydrochalcones, dihydroflavonols, and
chalcones were <5 mg/d, they were not included in the individual
subclass analyses. Total flavonoid intake was calculated by
summing each of the 219 flavonoid compounds.
Study outcomes
The primary outcome was first-time PAD hospitalization. PAD
hospitalization was defined as hospitalization with a primary or
secondary diagnosis code for atherosclerosis, aneurysm (aortic
and other), arterial embolism or thrombosis, or other PVD (ICD-
8 or ICD-10 as aforementioned). Other PVD diagnoses were
primarily unspecified PVD: more specifically, intermittent clau-
dication. Secondary outcomes were atherosclerosis, aneurysm
(aortic and other), arterial embolism or thrombosis, or other
PVD, discretely. These ICD codes for PAD hospitalization have a
positive predictive value of 81.2% in the Danish National Patient
Register (13).
PAD-related procedures
To assess the association between flavonoid intake and PAD-
related procedures, we obtained the following procedure codes
from the Danish National Patient Register: major amputation of
the lower extremities (above ankle), and vascular reconstruction
and endovascular procedures of the central or lower extremity
peripheral arteries (Supplemental Table 1). Because the Danish
National Patient Register only started recording procedure codes
in 1996, data were left truncated to 1 January, 1996. As
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because they died, and 9 participants were excluded because they
developed PAD, before 1 January, 1996 (n = 55,572).
Validated case analysis
To verify the registry-based outcomes, we re-examined
associations using only medically reviewed and validated cases
(ICD-10: I702, I702A, I739A, I739B, I739C), with follow-
up between August 1994 and December 2009. Validation was
undertaken by scrutinizing all medical records using prespec-
ified criteria for a diagnosis of PAD, as described in more
detail previously (13). Owing to prior diagnosis of validated
PAD, a further 7 participants were excluded in this analysis
(n = 55,640).
Covariates
Data on sex, age, education, smoking habits, alcohol consump-
tion, daily activity, and diet were obtained from questionnaires
completed by participants upon study enrollment. Smoking status
was defined as “current smoker” if the participant indicated that
they currently smoked daily, “previous smoker” if the participant
indicated that they smoked daily for ≥1 y at any stage of their
life, and “never smoker” if the participant was neither a current
nor a previous smoker, as defined above. Anthropometry and total
cholesterol were measured at the study centers. Mean annual
income over 5 y (defined as household income after taxation
and interest, using the value of the Danish currency in 2015)
was used to represent socioeconomic status. ICD-8 and ICD-10
codes were used to determine prevalent chronic kidney disease,
chronic obstructive pulmonary disease (COPD), ischemic heart
disease, ischemic stroke, heart failure, atrial fibrillation, and
cancers (Supplemental Table 2). For hypertension and diabetes
mellitus, self-reported data were used owing to underreporting
of these diagnoses in the Danish National Patient Register
(14).
Statistical analysis
Participants were followed from the date of enrollment until
the date of PAD hospitalization, death, emigration, or end of
follow-up (August 2017), whichever came first. Nelson–Aalen
plots of cumulative incidence for PAD with a competing risk
of death, as well as by quintiles of total flavonoid intake, were
computed. Quintiles were derived separately for each exposure
variable. Multivariable Cox proportional hazards models were
used to investigate relations between the exposures of interest
and all outcomes, fitting a separate model for each exposure
of interest and outcome combination. To allow the association
between the exposure and outcome to be nonlinear, the modeling
of continuous exposure variables was carried out using restricted
cubic splines using the “rms” R package with the rcs() function
[see (15) for a practical description of this]. For presentation
purposes (but not for modeling), quintiles of the exposure
variable were generated and the median value of each quintile was
calculated. HRs calculated from each of the aforementioned fitted
models, relative to a reference value of the median of the first
quintile of the relevant exposure variable, were plotted against
the exposure variable, with 95% confidence bands provided.
Using these values, HRs were calculated from the fitted models
comparing the median of each quintile to the reference value of
the median in quintile 1, and tabulated with 95% CIs. Individuals
with intakes >4 SDs above the mean were excluded from the
spline analysis. Four models of adjustment were used: 1) mini-
mally adjusted: age and sex; 1b) multivariable-adjusted: age, sex,
BMI, smoking status (current/former/never), physical activity
(total daily metabolic equivalent), pure alcohol intake (g/d),
and socioeconomic status (income); 2) multivariable-adjusted
including total energy intake and potential dietary confounders:
all variables in Model 1b plus energy intake (kJ/d) and intakes
(g/d) of fish, red meat, processed meat, PUFAs, MUFAs, and
SFAs; and 3) multivariable-adjusted including covariates that
may be on the causal pathway: all variables in Model 1b
plus hypertension (yes/no), hypercholesterolemia (yes/no), and
prevalent disease (stroke, ischemic heart disease, heart failure,
diabetes, COPD, chronic kidney disease, and cancer; entered
into the model separately). Covariates were chosen a priori to
the best of our knowledge of potential confounders of flavonoid
intake and PAD. Cox proportional hazards assumptions were
tested using log-log plots of the survival function against time
and assessed for parallel appearance. All deaths were censored
rather than treated as a competing risk (16). Because the presence
of major chronic diseases may influence the diet, as it was
captured at baseline, and result in a bias, we conducted a
sensitivity analysis where all participants with a comorbidity at
baseline were excluded. In addition, owing to no censoring in this
cohort, standard logistic regression models were used to obtain
the 20-y absolute risk estimates of PAD. For these analyses, a
binary outcome indicating the presence of PAD hospitalization
during 20 y of follow-up was used. Unless indicated by the
stratification variable, these estimates are for a nonsmoking
participant, aged 56 y, with a BMI (in kg/m2) of 25.5, a total
daily metabolic equivalent score of 56, with a mean household
income of 394,701–570,930 DKK/y, and an alcohol intake of
13 g/d. Emerging evidence suggests that flavonoids may afford
greater protection to those with lifestyle habits placing them
at a higher risk of cardiovascular disease (9); to investigate
whether the associations differed according to established risk
factors for PAD, firstly, P values for interaction terms were
obtained from likelihood ratio tests of Cox proportional hazards
models with and without the interaction term and, secondly, all
analyses were stratified by risk factors for PAD (17) for which
data had been collected at baseline (smoking status, alcohol
intake, BMI, sex, diabetes status, cholesterol concentrations,
and hypertension status). Because there is potential for residual
confounding, when stratifying by smoking status [never smoker
or ever smoker (current or previous smoker)], alcohol intake,
and BMI, the corresponding continuous variables (smoking pack-
years, alcohol intake, and BMI, respectively) were included in
the model where appropriate. We chose stratification cutoffs of
20 g pure alcohol per day and a BMI of 30 as done previously in
this cohort (11). All analyses were undertaken using STATA/IC
14.2 (StataCorp LLC) and R statistics (R Core Team, 2019)
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TABLE 1 Baseline characteristics of the study population1
Total population
(n = 55,647)
Total flavonoid intake quintiles
Characteristic Q1 (n = 11,130) Q2 (n = 11,129) Q3 (n = 11,130) Q4 (n = 11,129) Q5 (n = 11,129)
Total flavonoid intake, mg/d 496 [287–805] 174 [128–213] 321 [287–357] 496 [443–549] 727 [660–805] 1202 [1025–1436]
Sex, male 26,429 (47.5) 6417 (57.7) 5693 (51.2) 5290 (47.5) 4948 (44.5) 4081 (36.7)
Age, y 56 [52–60] 56 [52–60] 56 [52–60] 56 [52–60] 56 [52–60] 55 [52–59]
BMI, kg/m2 25.5 [23.3–28.2] 26.1 [23.8–28.9] 25.9 [23.6–28.5] 25.6 [23.3–28.3] 25.3 [23.2–27.9] 24.9 [22.7–27.4]
MET score 56.5 [37.0–84.8] 51.0 [32.0–78.0] 55.5 [36.3–84.0] 57.3 [38.0–85.0] 58.3 [38.5–87.0] 60.0 [39.8–88.5]
Smoking status
Never 19,628 (35.3) 2741 (24.6) 3740 (33.6) 3983 (35.8) 4444 (39.9) 4720 (42.4)
Former 16,027 (28.8) 2673 (24.0) 3017 (27.1) 3243 (29.1) 3563 (32.0) 3531 (31.7)
Current 19,992 (35.9) 5716 (51.4) 4372 (39.3) 3903 (35.1) 3122 (28.1) 2879 (25.9)
Education, y
≤7 18,248 (32.8) 5066 (45.5) 4222 (37.9) 3555 (31.9) 3006 (27.0) 2399 (21.6)
8–10 25,677 (46.1) 4876 (43.8) 5234 (47.0) 5326 (47.9) 5266 (47.3) 4975 (44.7)
≥11 11,694 (21.0) 1182 (10.6) 1669 (15.0) 2244 (20.2) 2850 (25.6) 3749 (33.7)
Mean household income, DKK/y
≤394,700 13,753 (24.7) 3293 (29.6) 2713 (24.4) 2685 (24.1) 2560 (23.0) 2502 (22.5)
394,701–570,930 13,914 (25.0) 3241 (29.1) 2993 (26.9) 2693 (24.2) 2582 (23.2) 2405 (21.6)
570,931–758,297 13,965 (25.1) 2918 (26.2) 3004 (27.0) 2879 (25.9) 2604 (23.4) 2560 (23.0)
>758,297 14,015 (25.2) 1678 (15.1) 2419 (21.7) 2872 (25.8) 3383 (30.4) 3663 (32.9)
Hypertensive 9006 (16.2) 1779 (16.0) 1832 (16.5) 1833 (16.5) 1808 (16.2) 1754 (15.8)
Hypercholesterolemic 4088 (7.3) 877 (7.9) 808 (7.3) 833 (7.5) 848 (7.6) 722 (6.5)
Comorbidities
Diabetes 1152 (2.1) 266 (2.4) 216 (1.9) 246 (2.2) 215 (1.9) 209 (1.9)
Heart failure 200 (0.4) 48 (0.4) 50 (0.4) 36 (0.3) 37 (0.3) 29 (0.3)
Atrial fibrillation 274 (0.5) 55 (0.5) 55 (0.5) 59 (0.5) 49 (0.4) 56 (0.5)
Ischemic heart disease 2101 (3.8) 546 (4.9) 404 (3.6) 424 (3.8) 383 (3.4) 344 (3.1)
Ischemic stroke 734 (1.3) 206 (1.9) 140 (1.3) 135 (1.2) 125 (1.1) 128 (1.2)
COPD 844 (1.5) 219 (2.0) 185 (1.7) 155 (1.4) 156 (1.4) 129 (1.2)
CKD 199 (0.4) 42 (0.4) 32 (0.3) 44 (0.4) 41 (0.4) 40 (0.4)
Cancer 241 (0.4) 52 (0.5) 42 (0.4) 58 (0.5) 33 (0.3) 56 (0.5)
Medication use
Insulin treated 374 (0.7) 76 (0.7) 64 (0.6) 82 (0.7) 81 (0.7) 71 (0.6)
Antihypertensive 6794 (12.2) 1339 (12.0) 1403 (12.6) 1381 (12.4) 1350 (12.1) 1321 (11.9)
Statin 1021 (1.8) 240 (2.2) 205 (1.8) 208 (1.9) 206 (1.9) 162 (1.5)
HRT
Never 15,885 (28.5) 2594 (23.3) 3031 (27.2) 3258 (29.3) 3248 (29.2) 3754 (33.7)
Current 8780 (15.8) 1291 (11.6) 1559 (14.0) 1687 (15.2) 1999 (18.0) 2244 (20.2)
Former 4521 (8.1) 819 (7.4) 842 (7.6) 887 (8.0) 928 (8.3) 1045 (9.4)
NSAID 17,998 (32.6) 3482 (31.5) 3496 (31.6) 3626 (32.8) 3606 (32.6) 3788 (34.3)
Aspirin 7009 (12.6) 1362 (12.2) 1343 (12.1) 1430 (12.8) 1382 (12.4) 1492 (13.4)
Dietary characteristics
Energy, kcal 2271 [1878–2717] 2060 [1681–2485] 2213 [1844–2629] 2330 [1944–2768] 2375 [1988–2828] 2373 [1975–2842]
Total fish intake, g/d 38 [25–55] 33 [22–49] 38 [25–54] 39 [27–57] 41 [28–59] 40 [27–57]
Red meat intake, g/d 78 [57–107] 80 [58–108] 81 [59–110] 80 [58–110] 78 [57–107] 72 [52–99]
Processed meat intake, g/d 25 [14–40] 28 [17–45] 26 [15–42] 25 [14–40] 23 [14–38] 20 [11–34]
Dietary fiber intake, g/d 20 [16–25] 17 [13–20] 19 [16–23] 21 [17–25] 22 [18–27] 23 [19–29]
Total carbohydrate intake, g/d 246 [201–297] 213 [174–256] 239 [199–285] 253 [208–303] 264 [217–316] 267 [218–323]
SFA, g/d 31 [24–39] 29 [23–37] 31 [24–39] 32 [24–40] 32 [25–41] 32 [24–41]
PUFA, g/d 13 [10–17] 12 [9–16] 13 [10–17] 14 [10–18] 14 [11–18] 14 [10–18]
MUFA, g/d 27 [21–35] 26 [20–34] 27 [21–35] 28 [22–35] 28 [22–35] 27 [21–34]
Fruit intake, g/d 172 [95–282] 88 [45–142] 162 [98–239] 193 [114–301] 225 [140–360] 240 [141–390]
Vegetable intake, g/d 162 [105–231] 115 [72–171] 150 [100–212] 168 [114–236] 185 [127–254] 196 [136–272]
Alcohol intake, g/d 13 [6–31] 11 [3–24] 13 [6–25] 15 [6–34] 14 [7–32] 13 [6–32]
1Values are medians [IQRs] or n (%), unless otherwise indicated. CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DKK, Danish
Krone; HRT, hormone replacement therapy; MET, metabolic equivalent; NSAID, nonsteroidal anti-inflammatory drug.
Results
This population of 55,647 Danish residents, with a median
[IQR] age of 56 [52–60] y at entry, had a median [IQR]
follow-up of 21 [20–22] y. During a maximum of 23 y of follow-
up, 2131 individuals were hospitalized for any form of PAD. For
PAD subtypes, 993 were hospitalized for atherosclerosis, 800
for an aneurysm, 161 for an embolism or thrombosis, and 653
for other PVD. Some participants received >1 PAD diagnosis.
During follow-up, 799 participants underwent revascularization
or endovascular surgery and 242 had a lower extremity ampu-
tation. Furthermore, 12,738 participants died from any cause
without a PAD hospitalization. Supplemental Figure 2 shows
the cumulative incidence of PAD hospitalizations and death
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FIGURE 1 Cubic spline curves describing the association between total flavonoid intake and both total PAD hospitalization events (A) and subtypes
of PAD (B) (n = 55,647). HRs and 95% CIs are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, physical activity,
socioeconomic status (income), and alcohol intake (Model 1b) and are comparing the specific amount of flavonoid intake (horizontal axis) with the median
intake for participants in the lowest intake quintile (174 mg/d). Compared with a total flavonoid intake of 174 mg/d, an intake of 1000 mg/d was associated
with a 32% lower risk of PAD (HR: 0.68; 95% CI: 0.60, 0.77), a 26% lower risk of atherosclerosis (HR: 0.74; 95% CI: 0.62, 0.88), a 28% lower risk of an
aneurysm (HR: 0.72; 95% CI: 0.59, 0.88), a nonsignificant 27% lower risk of an arterial embolism or thrombosis (HR: 0.73; 95% CI: 0.46, 1.13), and a 47%
lower risk of a hospitalization for other PVD (predominantly intermittent claudication) (HR: 0.53; 95% CI: 0.42, 0.67). PAD, peripheral artery disease; PVD,
peripheral vascular disease.
Baseline characteristics
Compared with participants with the lowest flavonoid intakes,
those with the highest habitual intakes were more likely to be
female, have a lower BMI, be more physically active, have a
higher degree of education, and have a higher income, and were
less likely to have ever smoked or to be hypercholesterolemic.
Furthermore, they tended to eat more fish, dietary fiber,
fruits, and vegetables, and eat less red and processed meat
(Table 1).
Associations between total flavonoid intake and PAD-related
hospitalizations and procedures
The association between total flavonoid intake and total
PAD hospitalizations was nonlinear; restricted cubic splines
showed a threshold of the inverse association at ∼750–1000
mg/d (Figure 1). Compared with a total flavonoid intake of
174 mg/d (median intake in quintile 1) and after multivariable
adjustments (Model 1b), an intake of 1000 mg/d was associated
with a 32% lower risk of a hospitalization for PAD (HR:
0.68; 95% CI: 0.60, 0.77). Figure 1 and Supplemental Table
3 show associations between total flavonoid intake and PAD
hospitalization subtypes. A total flavonoid intake of 1000 mg/d
was associated with a 26% lower risk of a hospitalization for
atherosclerosis (HR: 0.74; 95% CI: 0.62, 0.88), a 28% lower
risk of a hospitalization for an aneurysm (HR: 0.72; 95% CI:
0.59, 0.88), a nonsignificant 27% lower risk of a hospitalization
for an arterial embolism or thrombosis (HR: 0.73; 95% CI:
0.46, 1.13), and a 47% lower risk of a hospitalization for other
PVD (HR: 0.53; 95% CI: 0.42, 0.67). The association between
total flavonoid intake and PAD-related procedures appeared to
be “U-shaped” (Figure 2). Compared with a total flavonoid
intake of 174 mg/d, the lowest risks were seen for intakes
of 1000 mg/d for revascularizations/endovascular surgery (HR:
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FIGURE 2 Cubic spline curves describing the association between total flavonoid intake and total peripheral artery disease–related procedures
[revascularizations/endovascular surgery (A) and amputations (B)] in 55,572 participants of the Danish Diet, Cancer, and Health cohort. HRs and 95% CIs are
based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, physical activity, socioeconomic status (income), and alcohol intake
(Model 1b) and are comparing the specific amount of flavonoid intake (horizontal axis) with the median intake for participants in the lowest intake quintile (174
mg/d). Compared with a total flavonoid intake of 174 mg/d, an intake of 1000 mg/d was associated with a 43% lower risk of revascularizations/endovascular
surgery (HR: 0.57; 95% CI: 0.46, 0.69), and an intake of 500 mg/d was associated with a 44% lower risk of an amputation (HR: 0.56; 95% CI: 0.43, 0.74).
(HR: 0.56; 95% CI: 0.43, 0.74), after multivariable adjustments
(Model 1b). Associations were subtly strengthened, in that
HRs became more extreme, in a sensitivity analysis excluding
all participants with a comorbidity at baseline (n = 4779
excluded; n = 50,868 remaining in the analysis; data not
shown).
Associations between flavonoid subclass intakes and
PAD-related hospitalizations
For all flavonoid subclasses, after multivariable adjustments,
participants in quintiles 2–5 had a lower risk of a PAD
hospitalization than participants in quintile 1 (Table 2). HRs after
adjustments for covariates that are both confounders and on the
causal pathway (Model 3) are presented in Supplemental Table
4 but did not differ substantively. Associations were strongest
for the flavonol and flavanol oligo + polymers subclasses
where participants in quintile 5 had a 32% (Q5 compared with
Q1 HR: 0.68; 95% CI: 0.60, 0.77) and 33% (Q5 compared
with Q1 HR: 0.67; 95% CI: 0.59, 0.77) lower risk of a PAD
hospitalization, respectively, after multivariable adjustments
(Model 1b) (Table 2). All subclasses were nonlinearly associated
with PAD hospitalizations, with thresholds occurring at varying
amounts of intake (Figure 3).
Associations between major flavonoid compound intakes
and PAD-related hospitalizations
Table 3 and Figure 4 present associations between all
individual flavonoid compounds with mean intakes > 5 mg/d
and PAD hospitalizations. For the flavanol monomer subclass,
we present only the results for epicatechin because the flavanol
monomers are derived primarily from the same food sources, and
thus have a very high correlation (Pearson’s correlations ranged
from 0.89 to 1.00) and very similar HRs. Intakes above those in
quintile 1 for all individual flavonoid compounds were associated
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TABLE 2 HRs of PAD hospitalizations by quintiles of flavonoid and flavonoid subclass intakes1
Flavonoid intake quintiles
Q1 (n = 11,130) Q2 (n = 11,129) Q3 (n = 11,130) Q4 (n = 11,129) Q5 (n = 11,129)
Total flavonoids
Events, n 648 471 404 324 284
Intake,2 mg/d 174 [6–251] 321 [251–395] 496 [395–602] 727 [602–909] 1202 [909–3552]
HR (95% CI)
Model 1 Ref. 0.71 (0.65, 0.76) 0.55 (0.50, 0.61) 0.49 (0.44, 0.55) 0.47 (0.42, 0.53)
Model 1b Ref. 0.83 (0.77, 0.89) 0.73 (0.66, 0.80) 0.69 (0.61, 0.77) 0.69 (0.61, 0.78)
Model 2 Ref. 0.85 (0.79, 0.92) 0.77 (0.70, 0.85) 0.74 (0.65, 0.83) 0.75 (0.66, 0.86)
Flavonols
Events, n 699 443 385 321 283
Intake,2 mg/d 15 [0–21] 26 [21–32] 39 [32–50] 66 [50–83] 116 [83–251]
HR (95% CI)
Model 1 Ref. 0.70 (0.66, 0.75) 0.54 (0.49, 0.60) 0.46 (0.41, 0.51) 0.46 (0.40, 0.51)
Model 1b Ref. 0.81 (0.76, 0.87) 0.70 (0.63, 0.77) 0.65 (0.58, 0.73) 0.68 (0.60, 0.77)
Model 2 Ref. 0.82 (0.76, 0.88) 0.72 (0.65, 0.80) 0.69 (0.61, 0.78) 0.71 (0.62, 0.81)
Flavanol monomers
Events, n 670 451 398 333 279
Intake,2 mg/d 14 [0–21] 30 [21–46] 67 [46–116] 261 [116–282] 473 [282–916]
HR (95% CI)
Model 1 Ref. 0.83 (0.79, 0.87) 0.62 (0.55, 0.69) 0.48 (0.43, 0.54) 0.49 (0.44, 0.56)
Model 1b Ref. 0.91 (0.87, 0.96) 0.79 (0.70, 0.88) 0.71 (0.61, 0.80) 0.73 (0.65, 0.83)
Model 2 Ref. 0.93 (0.88, 0.98) 0.83 (0.73, 0.93) 0.78 (0.69, 0.89) 0.77 (0.68, 0.88)
Flavanol oligo + polymers
Events, n 683 452 382 322 292
Intake,2 mg/d 92 [0–136] 179 [136–217] 255 [217–303] 360 [303–434] 537 [434–2254]
HR (95% CI)
Model 1 Ref. 0.66 (0.61, 0.72) 0.54 (0.50, 0.59) 0.49 (0.44, 0.55) 0.45 (0.40, 0.51)
Model 1b Ref. 0.80 (0.74, 0.87) 0.71 (0.65, 0.78) 0.67 (0.60, 0.74) 0.67 (0.59, 0.77)
Model 2 Ref. 0.82 (0.75, 0.89) 0.75 (0.68, 0.82) 0.72 (0.64, 0.81) 0.69 (0.61, 0.78)
Anthocyanins
Events, n 566 392 364 424 385
Intake,2 mg/d 5 [0–10] 13 [10–17] 20 [17–24] 36 [24–53] 71 [53–397]
HR (95% CI)
Model 1 Ref. 0.66 (0.60, 0.72) 0.57 (0.52, 0.64) 0.63 (0.56, 0.70) 0.70 (0.62, 0.79)
Model 1b Ref. 0.81 (0.74, 0.88) 0.76 (0.68, 0.85) 0.79 (0.71, 0.88) 0.81 (0.72, 0.92)
Model 2 Ref. 0.84 (0.77, 0.92) 0.80 (0.72, 0.90) 0.83 (0.74, 0.94) 0.85 (0.75, 0.97)
Flavanones
Events, n 523 420 398 351 439
Intake,2 mg/d 3 [0–6] 9 [6–13] 18 [13–26] 32 [26–49] 70 [49–564]
HR (95% CI)
Model 1 Ref. 0.82 (0.76, 0.89) 0.70 (0.62, 0.80) 0.69 (0.61, 0.77) 0.77 (0.68, 0.86)
Model 1b Ref. 0.92 (0.85, 0.99) 0.85 (0.75, 0.96) 0.83 (0.74, 0.93) 0.90 (0.80, 1.01)
Model 2 Ref. 0.93 (0.86, 1.01) 0.88 (0.78, 1.00) 0.89 (0.79, 1.00) 0.94 (0.82, 1.06)
Flavones
Events, n 554 456 376 341 404
Intake,2 mg/d 2 [0–3] 4 [3–4] 5 [4–6] 7 [6–9] 11 [9–51]
HR (95% CI)
Model 1 Ref. 0.70 (0.63, 0.77) 0.63 (0.57, 0.70) 0.59 (0.53, 0.65) 0.63 (0.56, 0.71)
Model 1b Ref. 0.85 (0.77, 0.94) 0.80 (0.72, 0.89) 0.76 (0.68, 0.85) 0.81 (0.72, 0.91)
Model 2 Ref. 0.89 (0.80, 0.98) 0.85 (0.76, 0.95) 0.81 (0.72, 0.91) 0.90 (0.79, 1.02)
1HRs (95% CIs) for PAD hospitalizations during 23 y of follow-up, obtained from restricted cubic splines based on Cox proportional hazards models.
Model 1 adjusted for age and sex; Model 1b adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, and socioeconomic status (income);
Model 2 adjusted for all covariates in Model 1b plus energy intake and intakes of fish, red meat, processed food, PUFAs, MUFAs, and SFAs. PAD, peripheral
artery disease.
2Values are median [range].
Associations between total flavonoid intakes and PAD
hospitalizations stratified by risk factors for PAD
On a relative scale, the association between total flavonoid
intake and PAD hospitalizations appeared to differ according
to baseline smoking status, BMI, and diabetes status; higher
total flavonoid intakes were associated with a significantly
lower risk of PAD hospitalizations only in smokers, normal to
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FIGURE 3 HRs based on cubic spline curves to describe the association between flavonoid subclass intakes (mg/d) and total peripheral artery disease
hospitalizations among participants of the Danish Diet, Cancer, and Health cohort (n = 55,647). HRs and 95% CIs are based on Cox proportional hazards
models adjusted for age, sex, BMI, smoking status, physical activity, socioeconomic status (income), and alcohol intake (Model 1b) and are comparing the
specific amount of flavonoid intake (horizontal axis) with the median intake for participants in the lowest intake quintile.
(Figure 5). However, on an absolute scale, the 20-y absolute
risk difference between average male or female participants in
Q5 and those in Q1 was greatest for current smokers (male:
2.61%; female: 1.55%) and those with diabetes at baseline
(male: 2.11%; female: 1.27%); there was no difference based
on alcohol intake or BMI (Supplemental Tables 5 and 6).
The association did not differ according to sex, cholesterol
concentrations, or hypertension status on an absolute or a relative
scale (Figure 5, Supplemental Tables 5 and 6). Supplemental
Table 7 presents the sample size and number of events for each
subgroup.
Validated case analysis
Using only validated cases, 950 participants were hospitalized
for PAD. Compared with a total flavonoid intake of 174 mg/d
and after multivariable adjustments (Model 1b), an intake of
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TABLE 3 HRs of PAD hospitalizations by quintiles of flavonoid compound intakes1
Flavonoid intake quintiles
Q1 (n = 11,130) Q2 (n = 11,129) Q3 (n = 11,130) Q4 (n = 11,129) Q5 (n = 11,129)
Flavonols
Kaempferol
Events, n 674 451 388 335 283
Intake,2 mg/d 1 [0–1] 2 [1–3] 4 [3–8] 18 [8–20] 33 [20–68]
HR (95% CI)
Model 1 Ref. 0.82 (0.78, 0.86) 0.57 (0.51, 0.65) 0.50 (0.44, 0.56) 0.47 (0.41, 0.54)
Model 1b Ref. 0.89 (0.85, 0.94) 0.74 (0.65, 0.84) 0.73 (0.64, 0.82) 0.70 (0.62, 0.80)
Model 2 Ref. 0.91 (0.87, 0.96) 0.79 (0.70, 0.89) 0.78 (0.68, 0.88) 0.76 (0.67, 0.87)
Quercetin
Events, n 689 446 404 312 280
Intake,2 mg/d 12 [0–16] 20 [16–24] 29 [24–37] 46 [37–58] 78 [58–168]
HR (95% CI)
Model 1 Ref. 0.70 (0.66, 0.76) 0.55 (0.50, 0.60) 0.47 (0.42, 0.53) 0.45 (0.40, 0.51)
Model 1b Ref. 0.81 (0.75, 0.87) 0.70 (0.64, 0.77) 0.66 (0.59, 0.74) 0.67 (0.59, 0.76)
Model 2 Ref. 0.82 (0.76, 0.88) 0.72 (0.65, 0.80) 0.70 (0.62, 0.79) 0.71 (0.63, 0.82)
Flavanol monomers
Epicatechin
Events, n 666 480 396 308 281
Intake,2 mg/d 6 [0–9] 12 [9–15] 19 [15–25] 31 [25–39] 53 [39–155]
HR (95% CI)
Model 1 Ref. 0.69 (0.64, 0.75) 0.54 (0.49, 0.60) 0.47 (0.42, 0.52) 0.45 (0.40, 0.51)
Model 1b Ref. 0.82 (0.76, 0.88) 0.72 (0.65, 0.79) 0.67 (0.60, 0.75) 0.67 (0.59, 0.76)
Model 2 Ref. 0.84 (0.78, 0.91) 0.76 (0.68, 0.84) 0.72 (0.64, 0.81) 0.73 (0.64, 0.83)
Flavanol oligo + polymers
Procyanidin dimers
Events, n 674 447 389 324 297
Intake,2 mg/d 25 [0–37] 49 [38–62] 78 [62–94] 113 [94–138] 177 [138–510]
HR (95% CI)
Model 1 Ref. 0.68 (0.63, 0.73) 0.54 (0.49, 0.59) 0.50 (0.45, 0.56) 0.47 (0.41, 0.53)
Model 1b Ref. 0.81 (0.75, 0.88) 0.72 (0.65, 0.79) 0.69 (0.62, 0.78) 0.66 (0.58, 0.75)
Model 2 Ref. 0.84 (0.77, 0.91) 0.76 (0.68, 0.83) 0.74 (0.66, 0.83) 0.72 (0.63, 0.82)
Procyanidin trimers
Events, n 656 458 355 371 291
Intake,2 mg/d 10 [0–14] 17 [14–20] 23 [20–29] 35 [29–42] 54 [42–320]
HR (95% CI)
Model 1 Ref. 0.68 (0.63, 0.72) 0.55 (0.50, 0.60) 0.50 (0.45, 0.56) 0.49 (0.43, 0.55)
Model 1b Ref. 0.82 (0.76, 0.88) 0.72 (0.66, 0.79) 0.65 (0.58, 0.73) 0.61 (0.54, 0.69)
Model 2 Ref. 0.84 (0.78, 0.90) 0.75 (0.68, 0.82) 0.68 (0.61, 0.77) 0.65 (0.57, 0.75)
Flavanones
Hesperidin
Events, n 512 432 388 360 439
Intake,2 mg/d 2 [0–4] 6 [4–9] 12 [9–18] 24 [18–38] 54 [38–449]
HR (95% CI)
Model 1 Ref. 0.83 (0.76, 0.90) 0.72 (0.64, 0.81) 0.71 (0.64, 0.80) 0.77 (0.68, 0.87)
Model 1b Ref. 0.92 (0.85, 1.00) 0.87 (0.77, 0.98) 0.86 (0.77, 0.96) 0.91 (0.80, 1.02)
Model 2 Ref. 0.94 (0.87, 1.02) 0.90 (0.80, 1.02) 0.89 (0.80, 1.01) 0.96 (0.85, 1.09)
Flavones
Apigenin
Events, n 545 443 405 336 402
Intake,2 mg/d 2 [0–2] 3 [2–4] 5 [4–5] 6 [5–8] 10 [8–46]
HR (95% CI)
Model 1 Ref. 0.80 (0.74, 0.87) 0.68 (0.62, 0.75) 0.62 (0.56, 0.69) 0.67 (0.60, 0.75)
Model 1b Ref. 0.91 (0.84, 0.99) 0.83 (0.76, 0.92) 0.78 (0.70, 0.87) 0.84 (0.74, 0.94)
Model 2 Ref. 0.93 (0.85, 1.01) 0.87 (0.78, 0.96) 0.83 (0.74, 0.93) 0.92 (0.81, 1.05)
Anthocyanins
Cyanidin
Events, n 552 396 364 384 435
Intake,2 mg/d 1 [0–1] 1 [1–1] 2 [1–3] 4 [3–8] 17 [8–203]
HR (95% CI)
Model 1 Ref. 0.71 (0.67, 0.76) 0.58 (0.52, 0.65) 0.61 (0.55, 0.67) 0.82 (0.71, 0.94)
Model 1b Ref. 0.84 (0.79, 0.90) 0.75 (0.68, 0.84) 0.77 (0.70, 0.86) 0.90 (0.79, 1.04)
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TABLE 3 (Continued)
Flavonoid intake quintiles
Q1 (n = 11,130) Q2 (n = 11,129) Q3 (n = 11,130) Q4 (n = 11,129) Q5 (n = 11,129)
Delphinidin
Events, n 561 354 424 350 442
Intake,2 mg/d 0 [0–1] 1 [1–1] 2 [1–4] 5 [4–8] 18 [8–188]
HR (95% CI)
Model 1 Ref. 0.72 (0.66, 0.78) 0.60 (0.54, 0.68) 0.66 (0.59, 0.74) 0.86 (0.76, 0.98)
Model 1b Ref. 0.83 (0.76, 0.90) 0.75 (0.66, 0.85) 0.78 (0.70, 0.88) 0.89 (0.78, 1.01)
Model 2 Ref. 0.84 (0.77, 0.91) 0.77 (0.68, 0.87) 0.81 (0.72, 0.91) 0.93 (0.81, 1.05)
Malvidin
Events, n 661 567 234 330 339
Intake,2 mg/d 0 [0–1] 2 [1–6] 6 [6–6] 11 [6–14] 36 [14–114]
HR (95% CI)
Model 1 Ref. 0.77 (0.73, 0.82) 0.54 (0.48, 0.61) 0.54 (0.49, 0.61) 0.56 (0.48, 0.64)
Model 1b Ref. 0.86 (0.80, 0.91) 0.69 (0.61, 0.77) 0.68 (0.60, 0.76) 0.61 (0.51, 0.72)
Model 2 Ref. 0.86 (0.81, 0.92) 0.70 (0.62, 0.79) 0.69 (0.61, 0.78) 0.62 (0.52, 0.74)
1HRs (95% CIs) for PAD hospitalizations during 23 y of follow-up, obtained from restricted cubic splines based on Cox proportional hazards models.
Model 1 adjusted for age and sex; Model 1b adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, and socioeconomic status (income);
Model 2 adjusted for all covariates in Model 1b plus energy intake and intakes of fish, red meat, processed food, PUFAs, MUFAs, and SFAs. PAD, peripheral
artery disease.
2Values are median [range].
hospitalization (HR: 0.62; 95% CI: 0.51, 0.74) (Supplemental
Figure 2).
Discussion
A primary prevention approach incorporating nutrition strate-
gies may be advantageous in reducing the global burden and
considerable associated morbidity of PAD. In this prospective
cohort study, conducted in 55,647 Danish residents free of PAD
at baseline, higher intakes of total flavonoids and all flavonoid
subclasses were nonlinearly associated with a lower risk of PAD
hospitalizations. Furthermore, higher total flavonoid intakes were
associated with lower risks of hospitalizations for atherosclerosis,
aneurysms, and other PVD (primarily intermittent claudication),
and both revascularization or endovascular surgery and lower
extremity amputations. On both a relative and an absolute scale,
the greatest benefits observed for higher flavonoid intakes were
in current or former smokers.
The role that nutrition plays in the primary prevention of PAD
is not well understood. Previous observational studies suggested
that a diet characterized by low intakes of vitamins, dietary fiber,
and PUFAs, and a high intake of red meat, was associated with
a higher incidence of PAD (19–21). Owing to the underlying
pathogenesis of PAD, a review summarizing current knowledge
on nutritional patterns among patients with PAD strongly
advocated for a diet rich in foods with anti-inflammatory and
antioxidant properties (22). One such diet, the Mediterranean-
style diet, is characterized by high intakes of extra virgin olive oil,
vegetables, fruits, nuts and pulses, and legumes, and a moderate
intake of red wine, all of which are rich sources of flavonoids
(23). Evidence for the beneficial effects of the Mediterranean-
style diet in the primary prevention of PAD comes from a post hoc
analysis of the PREDIMED trial (24). However, there is a lack of
information on the potential benefits of a flavonoid-rich diet in
mitigating PAD. We have demonstrated that flavonoid intake is
inversely associated with atherosclerotic cardiovascular disease,
most strongly for PAD (9). In a previous case-control study
(n = 200), a higher flavonoid intake was associated with lower
odds of peripheral arterial occlusive disease, where the OR (95%
CI) for a 1-SD higher total flavonoid intake was 0.46 (0.28, 0.77)
(8). Furthermore, the strongest associations were observed for
the flavonol, flavone, and flavan-3-ols subclasses. In the present
study, inverse associations appeared to be the strongest for the
flavonol and flavanol oligo + polymers subclasses. It is likely
that tea, chocolate, wine, apples, and pears were the main food
sources of these subclasses in the present cohort (25). Although
caution must be taken when interpreting these findings because
they are on a relative scale, both true biological variability
and greater precision in the estimation of intakes of these
flavonoid subclasses may explain these stronger associations. The
inverse associations observed between flavonoid intake and both
revascularization or endovascular surgery and major amputation
procedures suggest that flavonoids may play a role not only
in the development of PAD, but also in the progression of
PAD.
The main risk factors for PAD—age, smoking, and dia-
betes mellitus—can cause an increase in inflammation, ar-
terial stiffness, and oxidative stress, and a decrease in NO
bioavailability with a concomitant decrease in vasodilation (7).
Flavonoids may impede the initiation and progression of PAD
by restoring endothelial homeostasis through the augmentation
of NO bioavailability and by attenuating inflammation through
upregulation of the anti-inflammatory nuclear factor erythroid
2-related factor 2 (Nrf2) pathway and downregulation of the
proinflammatory NF-κβ pathway (6). The present study found
that in current and former smokers, a higher flavonoid intake
was strongly associated with a lower risk of PAD, supporting
the hypothesis that flavonoids may play a role in counteracting
inflammation and oxidative stress in these participants. Setting
a precedent for this finding, an inverse association between
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FIGURE 4 HRs based on cubic spline curves to describe the association between major flavonoid compound intakes and total peripheral artery disease
hospitalizations among participants of the Danish Diet, Cancer, and Health cohort (n = 55,647). HRs and 95% CIs are based on Cox proportional hazards
models adjusted for age, sex, BMI, smoking status, physical activity, socioeconomic status (income), and alcohol intake (Model 1b) and are comparing the
specific amount of flavonoid compound intake (horizontal axis) with the median intake for participants in the lowest intake quintile.
be present only in current or former smokers (26). It may be
that flavonoids only exhibit detectable PAD-preventing effects
in settings of significant inflammation and oxidative stress, such
as that induced by smoking. That no significant association
was observed in nonsmokers, and statistical tests for interaction
were not significant, may be due to the very low number of
events in this subgroup. Importantly, although these findings
suggest that flavonoids may afford more protection against PAD
to smokers, smokers with a high flavonoid intake were still at
a higher risk of PAD than nonsmokers with a low flavonoid
intake. Although the HR of PAD was lower for high alcohol
consumers than for low alcohol consumers with a total flavonoid
intake >500 mg/d, the absolute risk difference between high
and low flavonoid intake for these 2 groups was comparable.
Similarly, although there was evidence that the associations
differed according to baseline BMI on a relative scale, the
absolute risk difference between high and low flavonoid intake
was the same for those who were normal or overweight and those
who were obese. Conversely, although on a relative scale there
was evidence that flavonoid intake was not associated with PAD
in persons with diabetes, on an absolute scale, the absolute risk
difference between high and low flavonoid intake for an average
male participant with diabetes was notable (2.11%). These
results should be interpreted with caution and warrant further
investigation because few participants had prevalent diabetes at
baseline (n = 1152). These findings suggest that the mechanisms
by which flavonoids ameliorate atherosclerosis may interact
with the mechanisms by which smoking and diabetes lead to
atherosclerosis.
Our results emphasize the importance of a flavonoid-rich
diet in mitigating PAD risk. Despite the positive findings of
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FIGURE 5 Multivariable-adjusted association between total flavonoid intake and total peripheral artery disease hospitalizations stratified by baseline
smoking status (P-interaction = 0.32), alcohol intake (P-interaction = 0.40), BMI (P-interaction = 0.12), sex (P-interaction = 0.12), diabetes status (P-
interaction < 0.01), cholesterol concentrations (P-interaction = 0.31), and hypertension status (P-interaction = 0.16). HRs and 95% CIs are based on Cox
proportional hazards models and are comparing the specific amount of flavonoid intake (horizontal axis) with the median intake for participants in the lowest
intake quintile (174 mg/d). All analyses were standardized for age, sex, BMI, smoking, physical activity, socioeconomic status (income), and alcohol intake
(Model 1b).
is urgently needed. Future interventional studies of flavonoid
intake should include patients at risk of PAD and investigate early
markers of PAD such as the ankle-brachial index.
Limitations
Owing to the observational nature of the study we were not
able to infer causality or rule out residual confounding. We
acknowledge common FFQ limitations, in particular that not all
flavonoid-rich foods, for example berries, were included in the
questionnaire. We acknowledge that flavonoid intake may have
changed over the 23 y of follow-up; however, this would have
likely attenuated any associations. Furthermore, the associations
observed cannot be attributed to flavonoid intake alone, because
participants with higher flavonoid intakes tended to have a
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vegetables and less red and processed meat. However, flavonoid
intake was strongly associated with PAD after adjustments were
made for a number of potential dietary confounders. We were
unable to determine the association between flavonoid intake and
outpatient visits for PAD, owing to the low validity of outpatient
diagnoses. Misclassification bias is always present when using
registry-based outcomes; however, our validated cases analysis
gave similar results meaning that bias was limited. Using clinical
measurements specific for PAD such as the ankle-brachial index
could have provided additional valuable information on PAD
severity and flavonoid intake.
Conclusion
A diet rich in flavonoids was strongly associated with a
lower risk of a hospitalization for PAD, revascularizations
or endovascular surgery, and lower extremity amputations.
Therefore, ensuring an adequate intake of flavonoid-rich foods
may be helpful in mitigating PAD risk.
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